32.03

3.58% -1.19

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$33.22

Offen:

$33.36

24-Stunden-Volumen:

1.07M

Relative Volume:

0.50

Marktkapitalisierung:

$3.15B

Einnahmen:

$669.43M

Nettoeinkommen (Verlust:

$-609.36M

KGV:

-5.2456

EPS:

-6.1061

Netto-Cashflow:

$-507.20M

1W Leistung:

-10.71%

1M Leistung:

+31.54%

6M Leistung:

+33.07%

1J Leistung:

+9.58%

1-Tages-Spanne:

$31.91

$33.58

1-Wochen-Bereich:

$31.81

$35.79

52-Wochen-Spanne:

$18.29

$39.89

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Firmenname

Ultragenyx Pharmaceutical Inc

Sektor

Healthcare (1092)

Branche

Biotechnology (614)

Telefon

415-483-8800

Adresse

60 LEVERONI COURT, NOVATO, CA

Mitarbeiter

1,371

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RARE Ultragenyx Pharmaceutical Inc	32.03	3.27B	669.43M	-609.36M	-507.20M	-6.1061
VRTX Vertex Pharmaceuticals Inc	476.31	121.89B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.12	69.52B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	859.43	54.49B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	184.97	39.11B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	281.26	38.46B	4.29B	577.22M	641.34M	4.2086

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-24	Herabstufung	Goldman	Buy → Neutral
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2025-05-28	Eingeleitet	William Blair	Outperform
2024-06-06	Hochstufung	Goldman	Neutral → Buy
2024-04-22	Eingeleitet	RBC Capital Mkts	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-06-14	Fortgesetzt	Credit Suisse	Outperform
2023-06-06	Hochstufung	Evercore ISI	In-line → Outperform
2023-04-26	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-18	Fortgesetzt	Canaccord Genuity	Buy
2022-12-30	Fortgesetzt	H.C. Wainwright	Buy
2022-11-03	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-10-13	Hochstufung	Guggenheim	Neutral → Buy
2022-08-01	Herabstufung	Evercore ISI	Outperform → In-line
2022-03-16	Hochstufung	Credit Suisse	Neutral → Outperform
2022-02-11	Hochstufung	JP Morgan	Neutral → Overweight
2021-09-30	Eingeleitet	H.C. Wainwright	Buy
2021-08-19	Eingeleitet	UBS	Sell
2021-07-15	Eingeleitet	Guggenheim	Neutral
2021-06-29	Hochstufung	BofA Securities	Neutral → Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-05-06	Hochstufung	Citigroup	Neutral → Buy
2021-05-06	Hochstufung	Evercore ISI	In-line → Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-03-02	Fortgesetzt	Stifel	Buy
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-07	Herabstufung	Wedbush	Outperform → Neutral
2020-11-24	Fortgesetzt	Evercore ISI	In-line
2020-11-12	Herabstufung	BofA Securities	Buy → Neutral
2019-08-02	Fortgesetzt	Wedbush	Outperform
2019-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Fortgesetzt	Raymond James	Outperform
2019-01-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2018-11-08	Hochstufung	Citigroup	Sell → Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Equal-Weight
2018-06-21	Herabstufung	Credit Suisse	Outperform → Neutral
2018-05-11	Hochstufung	Barclays	Equal Weight → Overweight
2018-05-10	Eingeleitet	Goldman	Neutral
2018-04-18	Hochstufung	SunTrust	Hold → Buy
2018-03-22	Fortgesetzt	Piper Jaffray	Overweight
2018-02-21	Bestätigt	Stifel	Buy
2018-01-22	Hochstufung	Evercore ISI	In-line → Outperform
2018-01-18	Eingeleitet	Credit Suisse	Outperform
2017-12-05	Bestätigt	Barclays	Equal Weight
2017-12-04	Hochstufung	Jefferies	Hold → Buy
2017-09-14	Hochstufung	Wedbush	Neutral → Outperform

Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Jul 13, 2026

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo

Jul 13, 2026

Jul 10, 2026

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

Jul 10, 2026

Jul 09, 2026

Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm

Jul 09, 2026

(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 09, 2026

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa

Jul 08, 2026

Ultragenyx releases 2025 impact report on rare disease work - Investing.com

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative

Jul 08, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire

Jul 08, 2026

Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan

Jul 08, 2026

Jul 07, 2026

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo

Jul 07, 2026

RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Jul 07, 2026

Jul 06, 2026

Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa

Jul 06, 2026

Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan

Jul 01, 2026

Jun 30, 2026

RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultrage - The National Law Review

Jun 30, 2026